Please login to the form below

Neupogen

This page shows the latest Neupogen news and features for those working in and with pharma, biotech and healthcare.

Novartis doubles down on biosimilars with Biocon alliance

Previous launches have included its Glatopa version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate) and Zarxio, a variant of Amgen’s Neupogen (filgrastim).

Latest news

Novartis takes biosimilar delay complaint to Supreme Court

Novartis is appealing an earlier ruling which ordered the company to delay launch of Zarxio, its version of Amgen's white blood cell stimulator Neupogen (filgrastim) and the first biosimilar to
Novartis claims first place for its biosimilar Enbrel in US

biosimilars business after the company got a green light for its Zarxio copy of Amgen's neutropenia therapy Neupogen (filgrastim).
Novartis gets FDA panel backing for biosimilar Enbrel

The GP2015 recommendation also puts Novartis on course for a second biosimilar approval in the US after its Zarxio product, a copy of Amgen's white blood cell stimulator Neupogen (filgrastim)
Sandoz files for approval of Neulasta biosimilar in Europe

The generic drug specialist - which also sells a biosimilar version of Amgen's short-acting GCSF product Neupogen (filgrastim) - said the Neulasta filing means it is now halfway to its objective
FDA panel recommends first biosimilar antibody for approval

The drug is also only the second biosimilar to be approved in the US after Novartis/Sandoz' Zarxio (filgrastim-sndz), which is a copy of Amgen's white cell stimulator Neupogen

More from news
Approximately 8 fully matching, plus 34 partially matching documents found.

Latest Intelligence

Customer experience rules the digital age

Establishing an effective customer journey
Embracing digital disruption in pharma

LEO Innovation Lab and some of its successes to date
Biosimilars - the same, but different?

Neupogen (filgrastim).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales

This was preceded by a period as marketing director for the oncology business unit of Amgen, where he worked on such products as Neulasta, Neupogen and Vectibix.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer, MedComms Agency: Salary TBC

Senior Medical Writer: Salary is DOE

Account Manager: Negotiable

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior Writer, Healthcare Advertising, London: Excellent package

Graduate Scientific Editor: DOE

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Market Access Consultant - Greater Manchester: Negotiable

Sudler London - Account Director: Competitive

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager- 4 days per week or full-time: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Subscribe to our email news alerts

PMHub

Add my company

Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....